Core Insights - Precipio, Inc. has amended its warrant exercise agreement with its largest warrant holder, changing the structure from cash exercise to a combination of cash and cashless exercise, resulting in a cash inflow of approximately $1.2 million instead of $3.8 million [1][6] Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to reduce cancer misdiagnoses through innovative diagnostic products and services that enhance accuracy and improve patient outcomes [3] Financial Impact - The amendment to the warrant exercise will reduce the number of shares added to the company's outstanding shares from approximately 300,000 to between 130,000 and 150,000, depending on the share price at the time of exercise [6]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly provided misleading statements about the safety of RP-A501 while concealing serious adverse events, including participant deaths during the clinical trial [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

So, our next guest says a lot of the good news is already priced into stocks, making further upside harder to come by, while high valuations meet high downside risks if earnings disappoint. Joining us now for more is Tom Bulick, CEO and managing partner at Strategy Asset Managers. Tom, uh, to what degree do we need to think about international markets as a risk versus an opportunity.I know you like Marcato Libre. We do. And thank you for having me on set today.and uh nice to be here. We we like uh the inter ...

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. due to alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false statements regarding the safety of its gene therapy ELEVIDYS for Duchenne, which posed significant risks to patients [2] - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, leading to potential halting of recruitment and dosing in trials, increased regulatory scrutiny, and risks to therapy approvals [2] - The defendants are accused of materially misleading investors and lacking a reasonable basis for their positive statements about ELEVIDYS [2] Group 2: Next Steps for Investors - Investors who suffered losses in Sarepta during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4] - The firm has over 70 employees and extensive expertise in complex securities litigation [4]

Market Overview - U.S. stocks traded mostly lower, with the Dow Jones index dropping over 250 points, down 0.60% to 44,382.58, while the NASDAQ rose slightly by 0.06% to 20,643.06, and the S&P 500 fell 0.23% to 6,266.23 [1] - European shares were lower, with the eurozone's STOXX 600 dipping 1.07%, Spain's IBEX 35 Index falling 0.99%, London's FTSE 100 down 0.47%, Germany's DAX 40 slipping 0.81%, and France's CAC 40 declining 0.94% [5] - Asian markets closed mixed, with Japan's Nikkei down 0.19%, Hong Kong's Hang Seng up 0.46%, China's Shanghai Composite gaining 0.01%, and India's BSE Sensex falling 0.83% [6] Company Earnings - WD-40 Co. (WDFC) reported better-than-expected earnings for its third quarter, although sales missed estimates. The company raised its FY2025 EPS guidance but narrowed its sales forecast [2] Stock Movements - MiNK Therapeutics, Inc. (INKT) shares surged 526% to $48.40 following a publication in Oncogene [8] - Ruanyun Edai Technology Inc. (RYET) shares increased by 19% to $18.37 after signing a strategic partnership with Confucius Institute at Prince Sultan University [8] - Signing Day Sports, Inc. (SGN) shares rose 98% to $2.4350 due to advancements in its business combination with One BlockchAIn [8] - Milestone Pharmaceuticals Inc. (MIST) shares dropped 41% to $1.5050 after announcing a public offering [8] - Federal Agricultural Mortgage Corporation (AGM) shares fell 11% to $175.20 following the announcement of the departure of its Chief Financial Officer [8] - TransMedics Group, Inc. (TMDX) shares decreased by 10% to $112.93 [8] Commodities - In commodity news, oil prices increased by 2.6% to $68.28, gold rose by 1.5% to $3,375.80, silver gained 4.1% to $38.830, while copper fell by 0.9% to $5.5425 [4]

Core Points - Holzer & Holzer, LLC is investigating Capricor Therapeutics, Inc. for potential compliance issues with federal securities laws following the receipt of a Complete Response Letter from the FDA regarding its Biologics License Application for Deramiocel [1] - The announcement of the CRL led to a decline in Capricor's stock price [1] Company Information - Capricor Therapeutics, Inc. trades on NASDAQ under the ticker CAPR [1] - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in litigation, including class action and derivative litigation [3] - The firm has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]

Core Insights - Moderna (MRNA) received FDA approval for its COVID-19 vaccine, Spikevax, for children aged six months to 11 years at increased risk for the disease [1][6] - The vaccine was previously available under Emergency Use Authorization [1][6] - Following the announcement, Moderna's shares increased by 4.5% [1] Group 1: FDA Approval and Vaccine Availability - Spikevax is now fully approved for adults aged 65 and above, and individuals aged six months to 64 years at increased risk for severe COVID-19 [2] - The updated Spikevax will be available for eligible patients during the 2025-2026 vaccination season in the U.S. [2][6] Group 2: Stock Performance - Year-to-date, Moderna's shares have decreased by 17.5%, while the industry has seen a growth of 0.2% [3] Group 3: Competitive Landscape - Other COVID-19 vaccines include Pfizer (PFE)/BioNTech's (BNTX) Comirnaty and Novavax's (NVAX) Nuvaxovid, with Comirnaty also using mRNA technology [4] - Novavax's Nuvaxovid is the only non-mRNA vaccine in the U.S. and has received full approval for older adults and high-risk individuals aged 12-64 [7] Group 4: Company Ranking - Moderna currently holds a Zacks Rank of 3 (Hold) [8]

Core Insights - Merus N.V. (MRUS) shares have increased by 29.9% over the past three months, driven by positive interim results from a phase II study of its bispecific antibody, petosemtamab (MCLA-158), in combination with Merck's Keytruda for treating PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) [1][4] Study Results - As of February 27, 2025, 45 patients were treated, with 43 deemed efficacy-evaluable, resulting in a confirmed overall response rate (ORR) of 63%, which included six complete responses and 21 partial responses [2] - The ORR varied with PD-L1 expression levels, showing a 73% ORR in patients with a combined positive score (CPS) greater than 20 and 47% in those with CPS 1–19 [2] - Median progression-free survival was reported at nine months, with an overall survival rate of 79% at 12 months [3] Safety Profile - The safety profile of the combination therapy was manageable, with no significant overlapping toxicities reported with Keytruda; treatment-related adverse events occurred in all patients, with infusion-related reactions observed in 38% [5][6] Future Prospects - The promising data suggests that the petosemtamab combination therapy could become a new standard of care for HNSCC, a cancer type with poor prognosis [6] - Merus is also conducting a registrational phase III study (LiGeR-HN1) for the combination therapy and another study (LiGeR-HN2) for petosemtamab monotherapy [7][8] Market Context - Merck's Keytruda, a leading anti-PD-1 therapy, generated $7.21 billion in sales in Q1 2025, reflecting a 6% year-over-year increase, and continues to expand into new indications and markets [8][10]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, in ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...